A | (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed. China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval. A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country. Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category. This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading. At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly. To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong. The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions. In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total. (By Tang Yuxian) 
。 8月9日，辽宁体彩借力辽宁省城市篮球联赛火热赛场，顺利开展体育彩票游戏价值推广暨安心购彩守护行动。活动立足群众体育场景，将竞猜游戏科普、涉彩反诈宣传、责任彩票推广融合，向广大球迷和市民普及理性购彩、安全购彩知识，切实筑牢群众购彩安全防线。依托篮球联赛的赛事氛围，辽宁体彩打造科普宣传现场。活动现场设置“远离圈套”“踢走骗局”两大趣味互动游戏，吸引众多参赛球员、赛场工作人员、球迷、市民踊跃参与，大家在轻松的游戏体验中，直观掌握防诈技巧，树立理性购彩理念，摒弃投机侥幸心理。现场同步开启“安心购彩守护小镇”扫码互动板块。市民扫码即可进入线上专属页面，随时浏览反诈案例、学习责任彩票知识和合规购彩技巧，实现“指尖学反诈、线上学科普”，全方位强化群众拒赌防诈的自我保护意识。现场摆放竞猜游戏基础知识科普展板、责任彩票、反诈警示宣传海报，直观展示理性购彩规范及体彩公益价值，普及体彩竞猜游戏基础知识，明确线下正规门店是合法购彩唯一渠道。 本次赛事宣传活动，以文体场景为载体，通过趣味互动+线上科普的模式，让责任彩票、反诈知识深入人心，提升群众理性购彩和风险防范意识。下一步，辽宁体彩将持续推进“安心购彩守护行动”常态化开展，深耕各类群众文体场景，丰富宣传形式、净化购彩环境，持续传递阳光、理性、合规的购彩新风，以公益责任助力全民健身事业发展。
Current article:http://h48plzi.bianneixuanbingqinyouxie.buzz/t4w4y0r/abi.html
Published on:14:42:08
